Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Portfolio Pulse from Vandana Singh
AstraZeneca and Daiichi Sankyo announced that their partnered cancer drug, datopotamab deruxtecan (Dato-DXd), met its primary goal in a phase 3 trial for breast cancer. The drug showed a significant improvement in progression-free survival compared to chemotherapy. The safety profile was consistent with previous trials, and no new safety issues were identified. The overall survival data is still being assessed. AstraZeneca's shares rose 2.66% in premarket trading following the news.
September 22, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's partnered cancer drug with Daiichi Sankyo met its primary goal in a phase 3 trial, leading to a 2.66% rise in premarket trading.
The positive trial results for AstraZeneca's partnered cancer drug with Daiichi Sankyo are likely to boost investor confidence, leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Daiichi Sankyo's partnered cancer drug with AstraZeneca met its primary goal in a phase 3 trial.
The positive trial results for Daiichi Sankyo's partnered cancer drug with AstraZeneca are likely to boost investor confidence, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Daiichi Sankyo's partnered cancer drug with AstraZeneca met its primary goal in a phase 3 trial.
The positive trial results for Daiichi Sankyo's partnered cancer drug with AstraZeneca are likely to boost investor confidence, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100